Urelumab Chemical Properties

form 

Liquid

color 

Colorless to light yellow

Urelumab Usage And Synthesis

Uses

Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity, and may enhance cytotoxic activity of Rituximab (HY-P9913). Urelumab can be used for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other types of non-Hodgkin lymphoma (NHL)[1].

Biological Activity

Urelumab has been used in trials studying the treatment of Leukemia, Multiple Myeloma, Malignant Tumors, and Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma. Urelumab is a fully human antibody that targets CD137. The antibody product was developed using Medarex's UltiMAb(R) technology and was the first UltiMAb- derived antibody in clinical development by Bristol-Myers Squibb under the December 2003 agreement with Medarex.

in vivo

target

4-1BB

References

[1] John Timmerman, et al. Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma. Am J Hematol. 2020 May;95(5):510-520. DOI:10.1002/ajh.25757
[2] Cheng LS, et al. A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicity. J Transl Med. 2022 Sep 8;20(1):415. DOI:10.1186/s12967-022-03619-w

Urelumab(934823-49-1)Related Product Information

• varlilumab
• Eptinezumab
• Atezolizumab
• Obinutuzumab
• Sutimlimab
• Utomilumab
• Glofitamab
• Nesvacumab
• Odronextamab
• Rituximab